Palta, M., Czito, B. G., Duffy, E., Malicki, M., Niedzwiecki, D., Abbruzzese, J. L., … Willett, C. (2018). A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity. In Journal of Clinical Oncology (Vol. 36, pp. 4121–4121). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.4121

Palta, Manisha, Brian G. Czito, Eileen Duffy, Mary Malicki, Donna Niedzwiecki, James L. Abbruzzese, Hope Elizabeth Uronis, Gerard C. Blobe, Dan G. Blazer, and Christopher Willett. “A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.” In Journal of Clinical Oncology, 36:4121–4121. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4121.

Palta M, Czito BG, Duffy E, Malicki M, Niedzwiecki D, Abbruzzese JL, et al. A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 4121–4121.

Palta, Manisha, et al. “A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 4121–4121. Crossref, doi:10.1200/jco.2018.36.15_suppl.4121.

Palta M, Czito BG, Duffy E, Malicki M, Niedzwiecki D, Abbruzzese JL, Uronis HE, Blobe GC, Blazer DG, Willett C. A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 4121–4121.